- UHRA Home
- Browsing by Author
Browsing by Author "Arachchillage, Deepa J."
Now showing items 1-3 of 3
-
Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock JACC Review Topic of the Week
Vandenbriele, Christophe; Arachchillage, Deepa J.; Frederiks, Pascal; Giustino, Gennaro; Gorog, Diana A.; Gramegna, Mario; Janssens, Stefan; Meyns, Bart; Polzin, Amin; Scandroglio, Mara; Schrage, Benedikt; Stone, Gregg W.; Tavazzi, Guido; Vanassche, Thomas; Vranckx, Pascal; Westermann, Dirk; Price, Susanna; Chieffo, Alaide (2022-05-17)Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), ... -
Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a) : Findings from a randomized controlled cross-over trial
Khan, Tina Z.; Gorog, Diana A.; Arachchillage, Deepa J.; Ahnström, Josefin; Rhodes, Samantha; Donovan, Jacqueline; Banya, Winston; Pottle, Alison; Barbir, Mahmoud; Pennell, Dudley J. (2019-09-01)Background: Raised lipoprotein(a) [Lp(a)] is a cardiovascular risk factor common in patients with refractory angina. The apolipoprotein(a) component of Lp(a) exhibits structural homology with plasminogen and can enhance ... -
Impact of Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy on Endogenous Fibrinolysis in Acute Coronary Syndrome: The VaLiDate-R study
Gue, Ying X.; Memtsas, Vassilios; Kanji, Rahim; Wellsted, David; Busby, Amanda; Smith, Megan; Vilar, Enric; Ryding, Alisdair; Arachchillage, Deepa J.; Gorog, Diana (2024-04)Background Impaired endogenous fibrinolysis is adverse cardiovascular risk factor in acute coronary syndrome (ACS) patients. Addition of very low dose rivaroxaban (VLDR) to dual antiplatelet therapy (DAPT) reduces ...